ArticleJournal of gastrointestinal oncology2026
Efficacy and safety of sintilimab-based neoadjuvant regimens in patients with resectable gastric or gastroesophageal junction adenocarcinoma: a single-arm systematic review and meta-analysis.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant immunotherapy has emerged as a research focus in the management of resectable gastric and gastroesophageal junction (G/GEJ) cancer. Sintilimab, a fully human anti-programmed death receptor-1 (PD-1) monoclonal antibody with high PD-1 affinity, demonstrates favorable antitumor activity, safety, accessibility, and cost-effectiveness, highlighting its potential in neoadjuvant settings. This single-arm meta-analysis aimed to provide pooled estimates of efficacy and safety by aggregating the rates of tumor response, R0 resection, survival, and toxicity of neoadjuvant sintilimab-based regimens in resectable G/GEJ adenocarcinoma. Methods: Original articles describing the safety and efficacy of sintilimab-based regimens for the neoadjuvant treatment of G/GEJ adenocarcinoma, published up to August 19, 2025, were retrieved from the Embase, PubMed/MEDLINE, Web of Science, and Cochrane Central Register of Controlled Trials. STATA 16.0 was employed for data analysis. Results: A total of 693 patients from 13 studies were included. Neoadjuvant sintilimab plus chemotherapy achieved pooled pathologic complete response (pCR) and major pathologic response (MPR) rates of 24% and 50%, respectively. Subgroup analyses showed higher pCR and MPR in prospective Conclusions: The pooled results indicate that the sintilimab-based neoadjuvant regimen offers promising efficacy and tolerability in G/GEJ adenocarcinoma. Subgroup analyses suggest higher pathological response in patients with PD-L1 CPS≥5 or MSI-H/dMMR. However, these exploratory findings require randomized controlled trials (RCTs) validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.